RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 10:05 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis study tests three different drug combinations in 430 people with advanced head and neck cancer that has spread or come back after immunotherapy stopped working. One group gets standard chemo plus cetuximab, another gets chemo plus bevacizumab, and a third gets bevacizumab pl…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:56 UTC
-
Could a Blood-Flow blocker boost chemo for head and neck cancer?
Disease control OngoingThis study tested whether adding the drug bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 400 adults took part. The goal was to see if the combination helped them live longer. Bevacizumab works by cutting off the tumo…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:35 UTC
-
Promising combo tackles tough head and neck cancers
Disease control OngoingThis study tests a combination of an immunotherapy drug (cemiplimab) and low-dose chemotherapy (paclitaxel and carboplatin) in 46 people with head and neck cancer that has returned or spread. The goal is to see if this mix can shrink tumors better than current treatments. Partici…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Marcelo Bonomi • Aim: Disease control
Last updated May 19, 2026 11:52 UTC
-
New combo shows promise for tough head and neck cancers
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with head and neck cancer that has come back or spread. About 52 adults with incurable, advanced cancer will take part. The goal is to s…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control OngoingThis study tested a three-drug combination (sorafenib, carboplatin, and paclitaxel) in 48 people with head and neck cancer that had spread or returned. The goal was to see if the combination could shrink tumors or slow cancer growth. Researchers also looked at how long the benefi…
Matched conditions: RECURRENT LARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:01 UTC